Cargando…
Revisiting Bevacizumab + Cytotoxics Scheduling Using Mathematical Modeling: Proof of Concept Study in Experimental Non‐Small Cell Lung Carcinoma
Concomitant administration of bevacizumab and pemetrexed‐cisplatin is a common treatment for advanced nonsquamous non‐small cell lung cancer (NSCLC). Vascular normalization following bevacizumab administration may transiently enhance drug delivery, suggesting improved efficacy with sequential admini...
Autores principales: | Imbs, Diane‐Charlotte, El Cheikh, Raouf, Boyer, Arnaud, Ciccolini, Joseph, Mascaux, Céline, Lacarelle, Bruno, Barlesi, Fabrice, Barbolosi, Dominique, Benzekry, Sébastien |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5784740/ https://www.ncbi.nlm.nih.gov/pubmed/29218795 http://dx.doi.org/10.1002/psp4.12265 |
Ejemplares similares
-
Model driven optimization of antiangiogenics + cytotoxics combination: application to breast cancer mice treated with bevacizumab + paclitaxel doublet leads to reduced tumor growth and fewer metastasis
por: Mollard, Severine, et al.
Publicado: (2017) -
Mathematical modeling for Phase I cancer trials: A study of metronomic vinorelbine for advanced non-small cell lung cancer (NSCLC) and mesothelioma patients
por: Barlesi, Fabrice, et al.
Publicado: (2017) -
Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Non‐Small Cell Lung Cancer
por: Schneider, Benjamin K., et al.
Publicado: (2019) -
A phase Ia/Ib clinical trial of metronomic chemotherapy based on a mathematical model of oral vinorelbine in metastatic non-small cell lung cancer and malignant pleural mesothelioma: rationale and study protocol
por: Elharrar, Xavier, et al.
Publicado: (2016) -
Deciphering the response and resistance to immune-checkpoint inhibitors in lung cancer with artificial intelligence-based analysis: when PIONeeR meets QUANTIC
por: Ciccolini, Joseph, et al.
Publicado: (2020)